REMED

What REMED does

REMED (주식회사 리메드) is a South Korean neuromodulation medical device manufacturer founded in 2003 and headquartered in Seongnam, Gyeonggi-do. The company develops non-invasive electromagnetic stimulation systems across five business segments: psychiatry and neurology (Transcranial Magnetic Stimulation/TMS for depression, anxiety, OCD, and stroke rehabilitation); physiology and pain management (Neural Magnetic Stimulation/NMS, Radial and Focused Shockwave Therapy/RSWT/FSWT, and RF systems); aesthetics; urology; and veterinary medicine. Its flagship products include the ALTMS TMS system (the first FDA-cleared TMS device in Asia) and the next-generation BrainStim series, alongside the Salus electromagnetic and shockwave product family. REMED serves hospitals, pain clinics, urology departments, and increasingly aesthetic and veterinary practices, holding approximately 90% of the domestic Korean TMS market with installations in 500+ facilities.

The company operates a multi-platform technology architecture built around electromagnetic coil engineering, hybrid cooling systems, 3D neuro-navigation (BrainEyes), 6-axis robotic transducer positioning, and a library of 40+ disease-specific protocols. Hardware spans portable helmet-type TMS (BrainStim 100), premium and entry-level Salus-Talent electromagnetic pain devices with up to 3.0 Tesla output, RSWT systems reaching 6 bar/21 Hz, and FSWT systems reaching 1 mJ/12 Hz. The portfolio is complemented by accessories including Myo1 EMG amplification modules, multi-angle TMS coils, and specialized treatment chairs.

REMED was listed on KOSDAQ in 2019 and currently operates through direct hospital sales in Korea, a network of 36+ domestic distributors and 26+ partner institutions, and international export to 30+ countries. International growth leverages OEM and licensing arrangements (notably with Germany's Zimmer and the US-based Compact II E) alongside a 2023-established REMED Japan regional headquarters and a 2023 five-year supply contract for pain treatment equipment to China. Revenue derives primarily from hardware sales of proprietary devices, supplemented by OEM/licensing revenue, with disclosed export revenue rising from $3 million (2018) to approximately $10 million (2021).

Name

REMED

Legal name

주식회사 리메드

Website

https://remed.kr

Company type

Public

Founded year

2003

Operating status

Operating

Short description

REMED is a Korean neuromodulation medical device manufacturer specializing in non-invasive electromagnetic stimulation systems, including TMS, NMS, RSWT/FSWT shockwave, and RF devices for psychiatry, pain management, urology, aesthetics, and veterinary markets, holding ~90% Korean TMS market share.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

• Transcranial magnetic stimulation devices
• Electromagnetic pain therapy
• Extracorporeal shockwave therapy
• Neuromodulation medical devices
• Non-invasive medical equipment

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: Sale of proprietary neuromodulation and pain management medical devices including TMS systems, NMS/pain management devices, shockwave therapy systems, urology devices, and veterinary products. Primary revenue stream through direct hospital/clinic sales and distributor networks domestically and internationally.
2. OEM & Licensing: Supply of core components and white-label manufacturing to major European companies and other partners under OEM contracts.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

REMED manufactures and sells non-invasive medical devices based on electromagnetic neuromodulation, including Transcranial Magnetic Stimulation (TMS) systems for psychiatry and neurology, pain management devices (PMS) using magnetic, RF, and shockwave technologies, urology devices, veterinary therapy systems, and aesthetic treatment solutions. The company sells primarily to hospitals, clinics, and partner institutions via direct sales, domestic distributors, and international export channels across 30+ countries.

Product overview

REMED is a Korean neuromodulation company offering a comprehensive portfolio of medical devices across five business segments: Psychiatry & Neurology (TMS), Physiology (PMS/RF/Shockwave therapy), Aesthetics, Urology, and Veterinary. The product architecture centers on two core technology platforms: Transcranial Magnetic Stimulation (TMS) systems including ALTMS (FDA-cleared, first in Asia), BrainStim (next-generation with hybrid cooling), and BrainStim 100 (portable helmet-type); and Pain Management Solutions (PMS) encompassing RF systems (Smart TMT), magnetic stimulation devices (Salus-Talent series), and shockwave therapy (Salus RSWT/FSWT series, Optimus Pro hybrid devices). The portfolio extends to urology (UI CUBE, Salus Talent-A/Pro-Aes), veterinary (Salus Talent Pro), and aesthetics (REMED Aesthetics with Liftan). Accessories include BrainEyes neuro navigation, Myo1 EMG module, TMS coils, treatment chair, and robotic arm. The products are primarily hardware-based medical devices with no public API offerings.

Differentiator

Problem solved

Functional benefit

Brands

• REMED Aesthetics: Face & body aesthetic brand leveraging REMED's 23 years of medical expertise in skin science. Includes products like Liftan and V1.

Products and services

• ALTMS FDA-cleared Transcranial Magnetic Stimulation system; the first FDA-cleared TMS system in Asia, used in over 500 Korean hospitals and clinics with approximately 90% domestic market share, exported to over 30 countries including the US, Japan, and Europe. Used to treat major depressive disorder, anxiety, OCD, and smoking addiction.
• BrainStim Next-generation high-performance TMS system with hybrid cooling system combining liquid and air cooling, featuring over 40 disease-specific protocols and personalized data save program for intensive and customized patient care. Designed for hospital psychiatry and neurology departments.
• BrainStim 100 Portable helmet-type TMS system designed to remove spatial and time limitations of conventional in-clinic TMS treatment, providing comfortable and simple therapy in the patient's preferred setting with safe adjustable intensity output.
• Smart TMT Smart RF system with intuitive UI, premium GlassTone handpieces, and S.S.F (Smart Safety Fusion) technology. Offers three personalized treatment modes: CET, RET, and Bipolar for skin, fascia, muscles, and joints.
• Salus-Talent Entry-level electromagnetic therapy device with one-touch operation featuring alternating LED laser and magnetic output; the entry-level Talent model offering core functionality of electromagnetic therapy.
• Salus-Talent-A A-Class magnetic pain therapy device with lightweight slim design, multiple protocols available, and 3D Angle Arm for targeted stimulation. High-end Talent model for advanced combination therapy.
• Salus-Talent-Pro Premium electromagnetic stimulator with two applicators for whole-body and localized stimulation, featuring 20 manual modes, 3D Angle Arm for flexible angles, and cooling system for continuous use. Offers 3.0 Tesla stimulation with multiple protocols.
• Salus Exms-A Compact and powerful magnetic therapy device designed for space efficiency, ease of use, and broad clinical applications with three detachable transducers by treatment area and 2.5 Tesla stimulation.
• Salus RSWT Flagship radial extracorporeal shockwave therapy system for effective muscle and fascia treatment across wide areas with therapy output up to 6 bar/21 Hz and titanium tip for enhanced performance.
• Salus-RSWT-A Compact radial shockwave solution for effective relief of muscle and fascia pain with guaranteed 3 million shots and optional titanium tip.
• Salus-FSWT-A Precise piezoelectric focused shockwave system for treating deeper pain points with higher accuracy, featuring output up to 1 mJ/12 Hz with guaranteed 5 million shots.
• Optimus Pro 2-in-1 system combining electromagnetic and extracorporeal shockwave therapy for optimal treatment experience with Max 6 bar and 3 Tesla output.
• Salus FSWT Duet Hybrid device combining radial and focused shockwave therapy functions, allowing selective treatment based on musculoskeletal pain type and condition with Max 6 bar-21 Hz and 1 mJ-12 Hz.
• Salus ESWT Expert All-in-one shockwave therapy system combining radial and focused shockwave therapy functions for expert users, with selective treatment based on pain type and condition.
• UI CUBE Kegel exercise induction stimulator that strengthens pelvic floor muscles using various intensity magnetic fields, enabling non-invasive treatment without undressing, skin contact, or invasive procedures (20 minutes/day, 3 times/week).
• Salus Talent-A (Urology) 3.0 Tesla A-Class stimulator for urinary incontinence treatment with various protocols, minimal noise, and maximized treatment improvement without direct pain or discomfort. Used in urology clinics for both men and women.
• Salus Talent-Pro-Aes (Urology) Professional high-tech solution for men's pelvic health that gently contracts and relaxes surrounding muscles, reducing pain and inflammation with 3.0 Tesla intensity. Targets male urinary dysfunction and post-surgical recovery.
• Salus Talent Pro (Veterinary) Magnetic stimulator for large animals designed for racehorse rapid recovery by improving blood circulation and treating inflammation. Recognized in the Japanese equestrian market.
• REMED Aesthetics Aesthetic sub-brand leveraging REMED's 23 years of medical expertise in skin science, featuring Liftan and other aesthetic treatment solutions for face and body applications. Targets physician offices and aesthetic clinics.

Quantifiable outcome

• Over 90% domestic TMS market share in Korea
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Seven partnerships are on record, tiered major and core.

• S Company (China)majorStrategic or Co-development Partner · 1 January 20235-year supply contract for pain treatment equipment to China's S company. Established in 2023 as a significant international commercial partnership.
• Zimmer (Germany)majorStrategic or Co-development PartnerSupply contract for Neural Magnetic Stimulation (NMS) products with German medical device company Zimmer, signed in 2017.
• Major European Companies (OEM)majorOEM/ Whitelabel/ Licensing PartnerOEM contract signed with major European companies in 2017 for supply of core neuromodulation components.
• Compact II E (USA)coreOEM/ Whitelabel/ Licensing PartnerOEM partnership for US pain management market entry in 2025, representing a significant strategic expansion into the US market.
• Korean Government / Ministry of Health and WelfarecoreStrategic or Co-development PartnerMultiple government project approvals including Ministry of Health and Welfare leading company designation (2010), Ministry of Industry dementia treatment device development project (2016), and electromagnetic field government project (2004).
• 36+ Domestic Distributors (Korea)coreChannel Partner/ Reseller/ DistributorNetwork of 36+ domestic distributors covering all regions of Korea for TMS, PMS, and other medical device distribution.
• 26+ Partner Hospitals (Korea)coreChannel Partner/ Reseller/ DistributorPartnerships with 26+ major hospitals and medical institutions in Korea including university hospitals for clinical collaboration and product deployment.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Dornier MedTech: Germany-based manufacturer of shockwave therapy and urology devices. Comparable to REMED in both the Salus shockwave pain management portfolio and the UI CUBE urology/electromagnetic pelvic-floor therapy products.
• Nexstim: Finland-based company offering navigated TMS systems with 3D neuronavigation, closely paralleling REMED's BrainEyes navigation and robotic-arm TMS positioning. Direct competitor in precision TMS delivery.
• MagVenture: Denmark-based manufacturer of clinical and research TMS systems used in hospitals and academic centers worldwide. Direct competitor in TMS hardware with overlapping customer profile to REMED.
• Magstim: UK-based pioneer in transcranial magnetic stimulation devices with the broadest installed base of research-grade TMS systems globally. Comparable to REMED in core TMS technology and neuroscience research customer base.
• Neurosoft: Russia-based manufacturer of TMS, EEG, and neurophysiology equipment with established international distribution. Comparable to REMED in non-invasive electromagnetic neuromodulation product portfolio.
• Brainsway: Israel-based manufacturer of Deep TMS (dTMS) systems for depression, OCD, and smoking addiction. Competes head-to-head with REMED in the psychiatric TMS category with similar FDA-cleared indications.
• Zimmer MedizinSysteme: Germany-based manufacturer of electromagnetic therapy and shockwave devices, and an existing REMED OEM customer (NMS supply contract signed 2017). Comparable in pain management electromagnetic technology and a peer across REMED's Salus-Talent line.
• BTL Group: Czech-based manufacturer of non-invasive medical aesthetic and physiotherapy devices including electromagnetic and shockwave platforms. Directly comparable to REMED's Smart TMT RF, Salus series, and REMED Aesthetics lines.
• Neuronetics: US-listed developer of the NeuroStar TMS system, the leading US TMS franchise for treatment-resistant depression. Directly comparable to REMED's ALTMS / BrainStim in indication, modality, and clinical customer base.
• Storz Medical: Switzerland-based global leader in focused and radial shockwave therapy systems (ESWT). Direct peer in REMED's Salus RSWT/FSWT pain management product line.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about REMED